The influence of market exclusivity on drug availability and medical innovations

被引：12

作者：

Glover, Gregory J. ^{[1
]}

机构：

[1] Pharmaceut Law Grp PC, Washington, DC 20036 USA

来源：

AAPS JOURNAL | 2007年 / 9卷 / 03期

关键词：

intellectual property; FDA; patents; Hatch-Waxman; market exclusivity; orphan drug exclusivity; pediatric exclusivity; patent term restoration; generic drugs; ANDA;

D O I：

10.1208/aapsj0903034

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The interpretation and application of intellectual property laws is enormously complex in the pharmaceutical industry, with companies needing to obtain multiple patents to fully protect their innovations. While patents provide important incentives for biomedical innovation and economic growth, concern has been expressed over the growing number of patents, the granting of patents on basic research tools (eg, genetically engineered animals), and the possibility that these legal protections may ultimately inhibit scientific advancement.

引用

页码：E312 / E316

页数：5

共 11 条

[1]

*CDCP US DEP HHS, 2006, HLTH US 2006

[2] Fostering innovation and discovery in biomedical research [J].

Cech, TR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (11) :1390-1393

[3]

DANZON P, PRICES AVAILABILITY

[4] New drug development in the United States from 1963 to 1999 [J].

DiMasi, JA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (05) :286-296

[5]

*FD CDER, 1998, GUID IND QUAL PED EX

[6]

*FDA, APPL DES ORPH PROD

[7]

MUELLER JM, 2001, 76 WASH L REV, V1, P10

[8]

*PHRMA, DEL PROM PHARM INN N

[9]

*PHRMA, 2005, PHARM IND PROF 2005

[10]

WAXMAN H, HEARING AFFORDABLE P

← 1 2 →